Full Press Release Details
BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy BBP-631 For Congenital Adrenal Hyperplasia.
BBIO
BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy BBP-631 For Congenital Adrenal Hyperplasia
Key Takeaway: BridgeBio Pharma Announces Dosing Of First Patient In Phase 1/2 Trial Of Investigational Gene Therapy BBP-631 For Congenital Adrenal Hyperplasia